Can Hemolytic Anemia Be Caused by MPN?
Yes, myeloproliferative neoplasms (MPNs) can be associated with anemia, but hemolytic anemia is not a typical or direct manifestation of MPNs themselves. The anemia seen in MPNs, particularly in myelofibrosis, is primarily due to ineffective hematopoiesis, bone marrow failure, and splenic sequestration—not hemolysis.
Understanding Anemia in MPNs
Primary Mechanisms of Anemia in MPN
The anemia that develops in MPNs, especially in primary myelofibrosis (PMF) and post-PV/ET myelofibrosis, occurs through:
- Ineffective hematopoiesis from bone marrow fibrosis and dysfunctional stem cells
- Bone marrow failure as the disease progresses
- Splenic sequestration from massive splenomegaly
- Hemodilution from expanded plasma volume
Transfusion-dependent anemia is actually a key prognostic indicator in myelofibrosis 1. The 2018 European LeukemiaNet guidelines specifically recommend allogeneic stem cell transplantation for transplant-eligible MF patients with intermediate-1 risk who present with "refractory, transfusion-dependent anemia" 1.
Treatment Approach to Anemia in MPN
For anemia management in myelofibrosis specifically, the guidelines recommend 2:
- Corticosteroids as first-line
- Androgens
- Erythropoiesis-stimulating agents (ESAs)
- Immunomodulators (such as thalidomide or lenalidomide)
These treatments target the underlying ineffective erythropoiesis, not hemolysis.
When Hemolytic Anemia Occurs with MPN
Secondary Autoimmune Hemolytic Anemia
If true hemolytic anemia occurs in an MPN patient, consider:
This is likely a secondary autoimmune hemolytic anemia (AIHA), not a direct consequence of the MPN itself. Approximately 50% of warm AIHA cases are secondary to other conditions, including lymphoproliferative disorders 3. Since MPNs can occasionally be associated with immune dysregulation or evolve with lymphoid features, secondary AIHA is possible but uncommon.
Diagnostic Approach
When evaluating anemia in an MPN patient, look for:
- Evidence of hemolysis: elevated LDH, indirect bilirubin, low haptoglobin, reticulocytosis, positive direct antiglobulin test (DAT/Coombs)
- Splenomegaly severity: massive splenomegaly suggests splenic sequestration rather than hemolysis
- Transfusion requirements: progressive transfusion dependence suggests marrow failure
- Bone marrow fibrosis grade: increasing fibrosis correlates with worsening anemia from ineffective hematopoiesis
Clinical Pitfalls
Do not assume anemia in MPN is hemolytic without laboratory confirmation. The vast majority of anemia in MPN patients, particularly myelofibrosis, is from:
- Bone marrow dysfunction
- Splenic pooling
- Hemodilution
If hemolysis is confirmed, treat it as secondary AIHA with standard AIHA protocols (corticosteroids ± rituximab) 3, while continuing to manage the underlying MPN.
Monitor for disease progression: worsening anemia in MPN may herald transformation to more aggressive disease states, including acute leukemia 4, 5.